Tesamorelin: Complete Guide to the Visceral-Fat GHRH Analogue

GHRH-analogue chemistry is a small family with meaningful structural differences. Sermorelin is GHRH(1-29) — the 29-amino-acid biologically active N-terminal fragment of native GHRH, with no enzymatic protection. Plasma half-life is roughly 11-12 minutes. CJC-1295 without DAC is a 30-amino-acid tetra-substituted GHRH(1-29) analogue with four point mutations (D-Ala2, Gln8, Ala15, Leu27) that extend half-life to approximately 30 minutes. CJC-1295 with DAC adds a maleimido-propionyl group that covalently binds plasma albumin, extending functional half-life to multiple days.^[10][11][12]

Tesamorelin sits between sermorelin and CJC-1295 without DAC on the chemistry axis — it is the full 44-amino-acid GHRH sequence rather than a 29-residue fragment, with a single hexenoic-acid modification rather than tetra-substitution. Its plasma half-life (~26 minutes) is similar to CJC-1295 no-DAC but the molecule itself is fundamentally different: it is closer to native GHRH structurally and has the only randomised-controlled-trial dataset in this class against a specific clinical endpoint.^[1][11][9]

The half-life table for orientation: native GHRH(1-44) — under 5 minutes; sermorelin GHRH(1-29) — 11-12 minutes; CJC-1295 no-DAC — ~30 minutes; tesamorelin — ~26 minutes; CJC-1295 with DAC — multiple days. None of these molecules is interchangeable with the others. The clinical literature behind each is separate.^[10][11][1]

The reason tesamorelin is the GHRH analogue with regulatory approval is a specific set of randomised controlled trials in a specific clinical population. The pivotal Falutz et al. NEJM 2007 trial was a 26-week phase-3 study (n=412) in HIV-infected patients with abdominal lipodystrophy randomised to tesamorelin 2 mg subcutaneous daily vs placebo. The primary endpoint was percent change in visceral adipose tissue (VAT) measured by CT. The tesamorelin arm showed approximately 15-18% relative reduction in VAT compared to placebo at 26 weeks, with the difference statistically significant and clinically meaningful for the studied indication.^[1][8]

The Stanley et al. JAMA 2014 follow-up examined effects on visceral fat and liver fat in the same HIV-LD population over 6 months, replicating the visceral-fat reduction and extending the readout to hepatic measures. The combined data package across these and supporting trials is what supported the FDA Egrifta approval. The mechanism is consistent with what would be expected from sustained GH-axis stimulation: visceral adipose tissue is preferentially lipolytic in response to GH signalling.^[2][7]

What the trials do not show is that tesamorelin produces equivalent visceral-fat reductions in non-HIV populations, in people with diet-and-exercise-responsive abdominal fat, or in cosmetic body-recomposition contexts. The population studied was specifically HIV-associated lipodystrophy — a metabolically distinct condition with its own visceral-fat biology. Extrapolation to general adult obesity is not what the published evidence supports.^[1][2]

A second wave of tesamorelin research, led primarily by Steven Grinspoon's group at Harvard, examined whether the visceral-fat effect also translated to reductions in hepatic fat fraction (HFF) in people with HIV-associated non-alcoholic fatty liver disease (NAFLD). The Stanley et al. 2018 J Clin Endocrinol Metab study reported absolute hepatic fat fraction reductions of ~5 percentage points in the tesamorelin arm versus placebo, with relative reductions exceeding 30% in some subgroups, measured by proton magnetic resonance spectroscopy.^[4][2]

The biological logic is consistent: visceral adipose tissue and hepatic fat are metabolically coupled, and GH-axis stimulation that reduces VAT often co-reduces hepatic fat in the same patients. The NAFLD reduction was a secondary endpoint and a research signal, not a registrational endpoint — tesamorelin is not approved as a NAFLD treatment by any agency.^[4]

These data are interesting for the broader GLP-1/GHRH/metabolic-peptide conversation about hepatic-fat reduction, but they should not be read as a general claim that tesamorelin treats NAFLD. The population was specifically HIV-LD with NAFLD, and the broader hepatology evidence base remains the GLP-1 receptor agonist class (semaglutide ESSENCE 2024, etc.).^[4][16]

Tesamorelin pharmacokinetics are not subtle. After a 2 mg subcutaneous injection in adults, peak plasma concentration occurs at approximately 15 minutes and the apparent terminal half-life is approximately 26 minutes. The drug is cleared rapidly. The downstream GH response is similarly time-limited: a single pulse of endogenous GH release from the pituitary that peaks 1-2 hours post-dose and resolves within 4-6 hours.^[1][5]

That pharmacology explains the daily-injection schedule and the timing recommendation (typically evening administration to align with the natural overnight GH pulse). It also explains why tesamorelin is fundamentally different from CJC-1295 with DAC: tesamorelin produces a brief discrete pulse; CJC-1295 with DAC produces sustained elevation. The clinical-evidence questions, the receptor-saturation biology, and the safety profiles all differ accordingly.^[12][13]

Serum IGF-1 levels rise on tesamorelin therapy as a downstream consequence of the repeated GH pulses, typically into the upper normal range or modestly above, depending on baseline. The FDA label flags IGF-1 monitoring as part of clinical oversight, with dose discontinuation considered if IGF-1 exceeds defined thresholds.^[5][1]

Tesamorelin's regulatory picture is asymmetric across the Atlantic. In the United States, the FDA approved tesamorelin acetate as Egrifta in November 2010 (Theratechnologies) and later approved the reformulated Egrifta SV in November 2019. Both approvals are for a single indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The label is specific to that population.^[5]

In the European Union, the EMA has not authorised tesamorelin. There is no EPAR for the molecule, and Egrifta has never been marketed in EU member states under the centralised authorisation procedure. This is not an oversight — it reflects the smaller HIV-LD population in the EU, the higher proportion of patients on antiretroviral regimens with lower lipodystrophy incidence, and a commercial decision not to pursue EMA filing.^[6][15]

For European buyers, this means tesamorelin sits outside the consumer-medicine framework entirely. It is not available by prescription in EU pharmacies through the centralised route, and any research use of the molecule belongs in a research context with appropriate oversight. Peptyds presents tesamorelin as a research peptide and does not market it as a consumer therapy.^[15][16]

The Egrifta clinical-trial safety database describes a recognisable set of side effects. Injection-site reactions (erythema, pruritus, pain, induration) are common — reported in the 20-25% range across pivotal trials. Arthralgia and peripheral oedema are reported at lower but meaningful frequencies, consistent with the broader pattern of GH-axis-stimulating therapies. Carpal tunnel symptoms can occur in a small minority of patients.^[1][3][5]

IGF-1 elevation is the headline biochemical signal. The label recommends monitoring IGF-1 at baseline, three months, and periodically thereafter, with dose discontinuation if levels exceed defined thresholds. The theoretical concern is that sustained high-normal-to-supraphysiological IGF-1 may interact with neoplasia biology — although the long-term clinical-trial data in the HIV-LD population did not identify a malignancy signal, the studied duration was not multi-decade.^[5][3]

Glucose tolerance can shift on tesamorelin, with documented increases in fasting glucose and HbA1c in a subset of patients. The label includes glucose monitoring guidance. Tesamorelin is contraindicated in active malignancy, pregnancy, and pituitary-axis disorders, and is not approved for paediatric use. These are physician-led considerations, not consumer self-monitoring rules.^[5]

Peptyds presents tesamorelin in its research format: a lyophilised research peptide in a sealed vial, with quality documentation, batch-traceable certificate of analysis, and the same cold-chain and storage standards as the rest of the catalogue. We do not present tesamorelin as a weight-loss treatment, a cosmetic body-recomposition product, or a NAFLD therapy.^[15][5]

The trial data is interesting and worth knowing. The 15-18% visceral-fat reduction in the HIV-LD trials is real, the NAFLD secondary signals are real, and the pharmacology has been characterised in a way that puts tesamorelin ahead of many research peptides on evidence depth. None of that translates to a consumer-marketing claim about general adult body composition. The honest frame is: this is a research peptide with a focused clinical-trial dataset in one specific population, no EMA authorisation, and a side-effect profile that requires medical oversight in any clinical application.^[1][2][16]

Anyone considering personal use of tesamorelin should hold that frame clearly. The molecule is regulated as a prescription medicine in the US, has no consumer-medicine pathway in the EU, and is on the WADA Prohibited List under the broader S2 peptide-hormones-and-mimetics category. Decisions about clinical use belong with a qualified healthcare professional.^[14][15]